ASCO 2017: A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiotherapy for high-risk prostate cancer

Over the past several years, we have seen a remarkable shift towards multiple treatment regimens at the onset of high-risk prostate cancer diagnosis, particularly in subsets of populations that likely derive the greatest benefit from up front aggressive therapy. Dr Mihalcik presented his group’s work of a post-hoc secondary analysis of RTOG 9902, a phase III trial of adjuvant chemotherapy with androgen suppression and radiotherapy for high-risk prostate cancer.
Uro Today